This study looks at how well teclistamab works with lenalidomide compared to lenalidomide alone. It focuses on people who have just been diagnosed with multiple myeloma. The goal is to see if the combination can help keep the cancer under control after a stem cell transplant.
The trial's ID number is NCT05243797. It is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. This trial is FDA-regulated and aims to include about 1,594 participants.
Who can join
Adults aged 18 and older, including men and women, can join this trial. Participants must have a new diagnosis of multiple myeloma and must not have received maintenance therapy before. Those with certain previous treatments or health issues may not be eligible. The trial team will confirm who can join.
Condition
Multiple Myeloma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into different groups by chance. One group will receive teclistamab with lenalidomide, another group will receive lenalidomide alone, and a third group will receive teclistamab alone. Each treatment will help the doctors see which is most effective in maintaining control of the cancer.
Where
This trial is enrolling at 42 locations. Recruiting sites are listed first.
Abramson Cancer Center University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Recruiting
AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group
Orlando, Florida
Recruiting
Banner University Medical Center Tucson, University of Arizona
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Directs the Lipper Myeloma Center, Dana-Farber. Treats multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.